a Biomedical Engineering Group, Department of Chemical Engineering .
b Department of Physiology , Tarbiat Modares University , Tehran , Iran , and.
Drug Deliv. 2016;23(3):1038-46. doi: 10.3109/10717544.2014.932861. Epub 2014 Jul 9.
Injectable In situ gel-forming chitosan/β-glycerol phosphate (CS/β-Gp) solution can be introduced into the body in a minimally invasive manner prior to solidifying within the target tissue. This hydrogel is a good candidate for achieving a prolonged drug delivery system for insulin considering its high molecular weight. In addition to the physicochemical characterization of this hydrogel, in vitro and in vivo applications were studied as a sustained insulin delivery system. In the in vitro release studies, 19-63% of total insulin was released from the CS/β-Gp hydrogel within 150 h at different β-Gp and insulin concentrations. The best formulation was selected for in vivo experimentation to control the plasma glucose of diabetic mice models. The hypoglycemic effect of this formulation following subcutaneous injection in diabetic mice lasted 5 d, significantly longer than that of free insulin solution which lasted several hours.
可注射原位凝胶形成的壳聚糖/β-甘油磷酸（CS/β-Gp）溶液可以在目标组织内固化之前以微创的方式引入体内。考虑到其高分子量，这种水凝胶是实现胰岛素长效药物递送系统的良好候选物。除了对这种水凝胶的理化特性进行表征外，还研究了其作为持续胰岛素递送系统的体外和体内应用。在体外释放研究中，在不同的β-Gp 和胰岛素浓度下，19-63%的总胰岛素在 150 小时内从 CS/β-Gp 水凝胶中释放出来。选择最佳配方进行体内实验，以控制糖尿病小鼠模型的血浆葡萄糖。这种配方在糖尿病小鼠皮下注射后的降血糖作用持续了 5 天，明显长于持续数小时的游离胰岛素溶液。
